Acrodermatitis Chronica Atrophicans Medication
- Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD more...
The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications. Various antibiotics are used to treat acrodermatitis chronica atrophicans (ACA).
Empiric antimicrobial therapy for ACA must be comprehensive and should cover all pathogens likely to be present in the context of this clinical setting.
Amoxicillin is bactericidal against Borrelia species. It is a semisynthetic penicillin of the aminopenicillin group that demonstrates a wide spectrum of bactericidal activity related to gram-positive and gram-negative bacteria. Its mechanism of action involves inhibition of
Doxycycline is a tetracycline antibiotic that inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. It is used for its antibacterial and anti-inflammatory effect and may be considered when there is concern about possible coexistent infection.
Ceftriaxone is bactericidal against Borrelia species. It is a third-generation cephalosporin with broad-spectrum gram-negative activity. Ceftriaxone has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. It arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Cefotaxime is a third-generation semisynthetic cephalosporin with broad-spectrum bactericidal activity against gram-negative bacteria and Staphylococcus and Streptococcus species. It is resistant to beta-lactamases. Its mechanism of action is related to inhibition of bacteria cell wall synthesis.
Penicillin G is a beta-lactam antibiotic. Its mechanism of action is related to inhibition of bacterial cell wall synthesis in the growth phase as a result of penicillin and bacterial transpeptidase binding.
Bhate C, Schwartz RA. Lyme disease: Part I. Advances and perspectives. J Am Acad Dermatol. 2011 Apr. 64(4):619-36; quiz 637-8. [Medline].
Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. J Am Acad Dermatol. 2011 Apr. 64(4):639-53; quiz 654, 653. [Medline].
Buchwald A. Ein Fall von diffuser idiopathischer Haut-Atrophie. Vrtljschr Derm. 1883. 10:553-6.
Herxheimer K, Hartmann K. Ueber Acrodermatitis chronica atrophicans. Arch f Dermatol u Syph (Wien). 1902. 61:57-76.
Smetanick MT, Zellis SL, Ermolovich T. Acrodermatitis chronica atrophicans: a case report and review of the literature. Cutis. 2010 May. 85(5):247-52. [Medline].
Aberer E. Country report - Austria. Report of WHO Workshop on Lyme Borreliosis Diagnosis and Surveillance, Warsaw. 1995.
Christova I, Komitova R. Clinical and epidemiological features of Lyme borreliosis in Bulgaria. Wien Klin Wochenschr. 2004 Jan 31. 116(1-2):42-6. [Medline].
Stinco G, Ruscio M, Bergamo S, Trotter D, Patrone P. Clinical features of 705 Borrelia burgdorferi seropositive patients in an endemic area of northern Italy. Scientific World Journal. 2014 Jan 16. 2014:414505. [Medline]. [Full Text].
Flisiak I, Schwartz RA, Chodynicka B. Clinical features and specific immunological response to Borrelia afzelii in patients with acrodermatitis chronica atrophicans. J Med. 1999. 30(3-4):267-78. [Medline].
Zalaudek I, Leinweber B, Kerl H, Mullegger RR. Acrodermatitis chronica atrophicans in a 15-year-old girl misdiagnosed as venous insufficiency for 6 years. J Am Acad Dermatol. 2005. 52:1091-4. [Medline].
Andres C, Ziai M, Bruckbauer H, Ring J, Hofmann H. Acrodermatitis chronica atrophicans in two children. Int J Dermatol. 2010 Feb. 49(2):180-3. [Medline].
Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H. Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology. 2008. 217(3):215-8. [Medline].
Lenormand C, Jaulhac B, Debarbieux S, Dupin N, Granel-Brocard F, Adamski H, et al. Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): A prospective study of 20 culture- and/or polymerase chain reaction (PCR)-documented cases. J Am Acad Dermatol. 2016 Apr. 74 (4):685-92. [Medline].
Danz B, Kreft B, Radant K, Marsch WCh, Fiedler E. Skin-coloured facial oedema as an initial manifestation of acrodermatitis chronica atrophicans. J Eur Acad Dermatol Venereol. 2008 Jun. 22(6):751-3. [Medline].
Mullegger RR, Glatz M. Skin manifestations of lyme borreliosis: diagnosis and management. Am J Clin Dermatol. 2008. 9(6):355-68. [Medline].
Wittmann D, Heppt M, Ruzicka T. [Acrodermatitis chronica atrophicans]. MMW Fortschr Med. 2016 Mar 31. 158 (6):64, 66-7. [Medline].
Maraspin V, Ogrinc K, Ruzic-Sabljic E, Lotric-Furlan S, Strle F. Isolation of Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection. 2011 Feb. 39(1):35-40. [Medline].
Brandt FC, Ertas B, Falk TM, Metze D, Boer-Auer A. Genotyping of Borrelia from formalin-fixed paraffin-embedded skin biopsies of cutaneous borreliosis and tick bite reactions by assays targeting the intergenic spacer region, ospA and ospC genes. Br J Dermatol. 2014 Sep. 171(3):528-43. [Medline].
Tee SI, Martinez-Escaname M, Zuriel D, et al. Acrodermatitis chronica atrophicans with pseudolymphomatous infiltrates. Am J Dermatopathol. 2013 May. 35(3):338-42. [Medline].